Apollo Endosurgery to Present at HC Wainwright Bioconnect Conference

January 5, 2021 4:05 PM

AUSTIN, TX / ACCESSWIRE / January 5, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures today announced that it will participate in the H.C. Wainwright Bioconnect 2021 Conference taking place virtually January 11-14, 2021. Management will provide a pre-recorded presentation which will be available to registered investors on demand via...

Read more

Experion to Webcast Live at VirtualInvestorConference.com on January 7, 2021

January 5, 2021 8:45 AM

VANCOUVER, BC / ACCESSWIRE / January 5, 2021 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) announced today that CEO, Mr. Jarrett Malnarich will present live at VirtualInvestorConferences.com on January 7, 2021 at 3:30 PM EST / 12:30 PM PST. Experion invites shareholders, investors, advisors, and analysts to attend the real-time, interactive investor presentation. This...

Read more

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

January 5, 2021 8:05 AM

FRAMINGHAM, MA / ACCESSWIRE / January 5, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present in a fireside chat at the H.C. Wainwright BioConnect 2021...

Read more

PHASTAR Announces Investment by Charterhouse Capital Partners

January 5, 2021 8:00 AM

Funding will Support Expansion of Statistics and Data Science Services and Geographic Reach DURHAM, NC and LONDON, UK / ACCESSWIRE / January 5, 2021 / PHASTAR, a specialist biometrics clinical research organization (CRO) for clinical trials, announces an investment made by Charterhouse Capital Partners LLP, a long-established European private equity firm, which will support PHASTAR's growth in biometrics and geographic expansion....

Read more

EV Biologics Update for 2021

January 4, 2021 9:00 AM

CHEYENNE, WY / ACCESSWIRE / January 4, 2021 / EV Biologics Corp (OTC:YECO) today announced that it has completed all its filings on OTC Markets with its 10K, 2020 filing today. The Company expects to become Pink Current within the next few weeks, then apply for a OTCQB listing. For the Company, being current allows the majority of brokers to trade in our shares, whereas before only online brokers could buy or sell the security. CEO Daniel...

Read more

MJ BIOTECH, INC., Signs Agreement with INVEST AFRICA GLOBAL LLC to provide PPE and COVID-19 Coronavirus 'Rapid Test Kits'

December 31, 2020 8:00 AM

CHEYENNE, WY / ACCESSWIRE / December 31, 2020 / MJ Biotech Inc. (OTCQB:MJTV), today announced that it has signed an agreement with Invest Africa Global LLC (IAG) to provide PPE and Covid-19 Coronavirus "Rapid Test Kits" to the Hospitals and other Medical professionals. MJTV chose this Partnership with AIG due to their vast distribution and sales network in local and international locales. IAG has developed relationship with...

Read more

Mosaic ImmunoEngineering Inc. Announces Stock Symbol Change to “CPMV”

December 30, 2020 5:10 PM

NOVATO, CA / ACCESSWIRE / December 30, 2020 / Mosaic ImmunoEngineering Inc., (the "Company" or "Mosaic") (OTC PINK:PTSCD), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, announced today that The Financial Industry Regulatory Authority, Inc., (FINRA), has approved a change in the Company's stock...

Read more

Helix BioPharma Corp. Closes Private Placement

December 30, 2020 5:00 PM

RICHMOND HILL, ON / ACCESSWIRE / December 30, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $3,000,000. The terms of the placement are for the purchase of...

Read more

Hancock Jaffe Announces Executive Promotions

December 30, 2020 4:15 PM

IRVINE, CA / ACCESSWIRE / December 30, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Hamed Alavi has been promoted to Vice President of Research and Development and Quality and that Craig Glynn has accepted the position of Chief Financial Officer. Dr. Alavi joined Hancock Jaffe in August of 2020 as the Director of...

Read more

Wuhan General Group Announces $450,000 USD Private Placement by ThreeD Capital Inc.

December 30, 2020 9:00 AM

CAPE TOWN, SA / ACCESSWIRE / December 30, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update: The Company is pleased to announce a private placement financing of $450,000.00 USD with ThreeD Capital Inc. In consideration, the Company will...

Read more

Edesa Biotech Issues Letter to Shareholders

December 30, 2020 8:00 AM

TORONTO, ON / ACCESSWIRE / December 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, Par Nijhawan, providing a review of 2020. Dear Fellow Shareholders, It would be difficult to begin any year-end review without acknowledging the impact that the global health crisis has had on our communities and families, our economy, and on our...

Read more

Tetra Bio-Pharma Files New Drug Submission for REDUVO(TM) in Canada

December 30, 2020 6:30 AM

The addressable market is estimated to be $80M CDN by 2022 Tetra meets another key milestone before the end of the year OTTAWA, ON / ACCESSWIRE / December 30, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the New Drug Submission (NDS) for the Dronabinol Soft Gel capsules, has been filed with Health...

Read more

Meeting DEA Control Requirements - St Regis Mohawk Tribe to Develop Marijuana Grow Facility with MMJ BioPharma Cultivation and Excellis Health Solutions

December 28, 2020 2:45 PM

ST. PETERSBURG, FL / ACCESSWIRE / December 28, 2020 / MMJ Biopharma Cultivation, the premier medical cannabis cultivation and research company, today announced the signing of an agreement with Excellis Health Solutions, a global provider in end-to-end supply chain services to the life sciences industry. Excellis Health Solutions will be facilitating the movement and supply chain logistics of MMJ Biopharma Cultivation's marijuana products to...

Read more

Wuhan General Group Launches Hemp Product Research & Development Division

December 23, 2020 10:25 AM

CAPE TOWN, SA / ACCESSWIRE / December 23, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update: The Company is pleased to inform its shareholders that it is positioning itself in the rapidly expanding hemp industry by launching the M2BIO Hemp Product...

Read more

OMNICANNA Appoints Thermic Paint Partner, Jean-Christophe Gerard, to the Board of Directors and Operations Responsibility of Chief Technology Officer (CTO), Ignites OMNICANNA/Thermic Acquisition with New Consumer Product Lines and Revenue Growth Through USA Expansion Plans

December 23, 2020 9:15 AM

NASHVILLE, TN / ACCESSWIRE / December 23, 2020 / Omnicanna Health Solutions, Inc. (OTC PINK:ENDO), a U.S. Company specializing in hemp formulation-based health and wellness solutions, is pleased to announce it has appointed Mr. Jean-Christophe Gerard to the Company Board of Directors and operations responsibility of Chief Technology Officer (CTO). Mr. Gerard's successful engineering background and firsthand knowledge at Thermic developing...

Read more

Helix BioPharma Corp. Finalizes Polish Subsidiary Divestiture

December 22, 2020 5:00 PM

RICHMOND HILL, ON / ACCESSWIRE / December 22, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has closed the transaction with CAIAC Fund Management AG ("CAIAC") for the Company's remaining holdings in its Polish...

Read more

BioSpyder Announces Direct-to-Consumer COVID-19 Screening Service

December 22, 2020 8:00 AM

"TestTheTeam" is a convenient, cost effective test kit for your business or family SAN DIEGO, CA / ACCESSWIRE / December 22, 2020 / BioSpyder Technologies, Inc. is announcing it is selling COVID-19 surveillance screening kits to businesses and consumers via its new ecommerce site testtheteam.com (live on Tuesday, December 22). The service, which utilizes the BioSpyder TempO-SPan technology, aims to relieve the pressure on...

Read more

Still Time for Federal Government to Act to Protect Patient Access to New Medicines and Vaccines Before January 1, 2021 Implementation of New PMPRB Regulations and Guidelines

December 21, 2020 9:30 AM

OTTAWA, ON / ACCESSWIRE / December 21, 2020 / Innovative Medicines Canada (IMC) issued the following statement today warning of the impact the Patented Medicines Prices Review Board's (PMPRB's) Final Regulations and Guidelines will have on Canadians' access to new medicines and vaccines if they come into effect January 1, 2021: "Innovative Medicines Canada remains extremely concerned with the Patented Medicine Prices Review...

Read more

Wuhan General Group Updates on Second Scientific Paper Published on Psychedelics

December 21, 2020 9:15 AM

CAPE TOWN, SA / ACCESSWIRE / December 21, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update: The research team funded by Wuhan General Group has successfully published a second paper on psychedelic science. This paper is entitled "Effects...

Read more

Results of General Meeting of Shareholders Held December 17, 2020

December 21, 2020 9:00 AM

SYDNEY, AUSTRALIA / ACCESSWIRE / December 21, 2020 / Parnell Pharmaceuticals Holdings Ltd (OTC PINK:PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced the results of the resolution presented at its General Meeting of Shareholders held December 17, 2020 (Australian Eastern Standard Time). Submission of Matters to a Vote of...

Read more